Coeptis Therapeutics Holdings, Inc. News
-
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor’s Distinguished Research Award
April 2, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing…
-
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR…
-
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which…
-
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
January 4, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
Coeptis Therapeutics to Present at the Emerging Growth Conference
December 4, 2023 (Source) — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing…
